CAMBRIDGE, Mass., Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, prior to the open of financial markets.
Akebia will host a conference call on Thursday, August 8, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please dial (800) 715-9871 (USA & Canada - Toll-Free) and enter Conference ID: 4155557.
A live webcast of the conference call will be available via the Investors section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.06 |
| Daily Change: | 0.16 8.42 |
| Daily Volume: | 4,529,430 |
| Market Cap: | US$449.450M |
March 25, 2025 December 18, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
